# Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid

> **NCT01634100** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Probenecid
- **DRUG:** Rifampicin
- **DRUG:** Empagliflozin
- **DRUG:** Empagliflozin
- **DRUG:** Rifampicin
- **DRUG:** Probenecid
- **DRUG:** Empagliflozin (BI 10773)

## Key facts

- **NCT ID:** NCT01634100
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01634100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01634100, "Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01634100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*